Lesson plan
Propylallyltryptamine
Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). The chemical synthesis of PALT has been described. A notable analogue of PALT is iPALT (ASR-3003). PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
Article summary
Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). The chemical synthesis of PALT has been described. A notable analogue of PALT is iPALT (ASR-3003). PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.